UH research team receives grant to fight aggressive pediatric cancer

cancer research

A team of researchers at the University of Houston is working to develop a new treatment for Rhabdomyosarcoma, an aggressive cancer with a higher incidence in young children. Photo via Getty Images.

Researchers at the University of Houston have received a $3.2 million grant from the National Institutes of Health to help find innovative ways to treat Rhabdomyosarcoma, or RMS.

According to a statement from the university, RMS is a malignant soft tissue sarcoma that has a higher incidence in young children and is responsible for 8 percent of pediatric cancer cases with a relatively low survival rate.

One way UH is working on the issue is by studying how and why RMS cells, which are found most often in muscle tissue, divide uncontrollably without ever maturing into normal muscle cells. The researchers aim to tackle a target inside RMS cells known as TAK1, which plays a key role in regulating cell growth.

“By targeting TAK1, we aim to stop the cancer at its source and help the cells develop normally,” Ashok Kumar, the Else and Philip Hargrove Endowed Professor of Drug Discovery at the UH College of Pharmacy and director of the Institute of Muscle Biology and Cachexia, said in a news release. “This approach could lead to new and better treatments for RMS.”

According to UH, preliminary results demonstrated that TAK1 is highly activated in embryonal RMS cells, which are found in younger children; alveolar RMS cells, which are found in older children and teens; and human RMS samples. This suggests that the protein plays a major role in the development of this form of cancer.

The team still aims to uncover how the protein helps RMS cancer grow and plans to evaluate how blocking TAK1 can be used as a therapeutic.

“Blocking TAK1, either by changing the genes (genetic approaches) or using drugs (pharmacological approaches), can stop certain harmful behaviors in cancer cells,” Kumar added. “This was tested both in lab-grown cells and in living models, showing that TAK1 is a key target to control RMS cancer’s spread and aggressiveness, and inhibits tumor formation.”

From Your Site Articles

Innovators in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies have joined TMC's Accelerator for Cancer Therapeutics. Photo courtesy TMC.

TMC names 2025 cohort of cancer treatment innovators

ready to grow

Texas Medical Center Innovation has named more than 50 health care innovators to the fifth cohort of its Accelerator for Cancer Therapeutics (ACT).

The group specializes in immunotherapy, precision drug discovery, monoclonal antibodies, and diagnostic and therapeutic technologies, according to a statement from TMC.

During the nine-month ACT program, participants will enjoy access to a network of mentors, grant-writing support, chemistry resources, and the entrepreneur-in-residence program. The program is designed to equip participants with the ability to secure investments, develop partnerships, and advance the commercialization of cancer therapeutics in Texas.

“With over 35 million new cancer cases predicted by 2050, the urgency to develop safer, more effective, and personalized treatments cannot be overstated,” Tom Luby, chief innovation officer at Texas Medical Center, said in a news release.

Members of the new cohort are:

Alexandre Reuben, Kunal Rai, Dr. Cassian Yee, Dr. Wantong Yao, Dr. Haoqiang Ying, Xiling Shen, and Zhao Chen, all of the University of Texas MD Anderson Cancer Center
Dr. Andre Catic and Dr. Martin M. Matzuk, both of the Baylor College of Medicine
Cynthia Hu and Zhiqiang An, both of UTHealth Houston
Christopher Powala, Aaron Sato, and Mark de Souza, all of ARespo Biopharma
Daniel Romo, Dr. Susan Bates, and Ken Hull, all of Baylor University
Eugene Sa & Minseok Kim, both of CTCELLS
Gomika Udugamasooriya and Nathaniel Dawkins, both of the University of Houston
Dr. Hector Alila of Remunity Therapeutics
Iosif Gershteyn and Victor Goldmacher, both of ImmuVia
João Seixas, Pedro Cal, and Gonçalo Bernardes, all of TargTex
Ken Hsu and Yelena Wetherill, both of the University of Texas at Austin
Luis Martin and Dr. Alberto Ocaña, both of C-Therapeutics
Dr. Lynda Chin, Dr. Keith Flaherty, Dr. Padmanee Sharma, James Allison, and Ronan O’Hagan, all of Project Crest/Apricity Health
Michael Coleman and Shaker Reddy, both of Metaclipse Therapeutics
Robert Skiff and Norman Packard, both of 3582.ai
Rolf Brekken, Uttam Tambar, Ping Mu, Su Deng, Melanie Rodriguez, and Alexander Busse, all of UT Southwestern Medical Center
Ryan Swoboda and Maria Teresa Sabrina Bertilaccio, both of NAVAN Technologies
Shu-Hsia Chen and Ping-Ying Pan, both of Houston Methodist
Thomas Kim, Philipp Mews, and Eyal Gottlieb, all of ReEngage Therapeutics

The ACT launched in 2021 and has had 77 researchers and companies participate. The group has collectively secured more than $202 million in funding from the NIH, CPRIT and venture capital, according to TMC.

The new center is specifically designed to allow patients to be on the cutting edge of testing brand-new therapies that could save their lives.

Houston cancer-fighting organization launches center to support early clinical trials

new to hou

Cancer treatment in Houston just became even more promising — and forward-thinking.

Phase 1 clinical trials are necessary to prove the efficacy in humans of treatments that have appeared promising in lab trials. In the name of cancer-fighting innovation, Baylor College of Medicine’s Dan L. Duncan Comprehensive Cancer Center has launched the Albert and Margaret Alkek Foundation Center for Experimental Therapeutics.

The new center is specifically designed to allow patients to be on the cutting edge of testing brand-new therapies that could save their lives.

“Clinical trials are critical for advancing the field of oncology and improving outcomes for cancer patients. Phase 1 trials are the first step in bringing innovative therapies to the clinic,” says Dr. Benjamin Musher, Barry S. Smith endowed professor at Baylor and medical director of medical oncology at the Duncan Cancer Center McNair Campus, in a news release. “Our new program will build on the success of previous phase 1 trials at Baylor and provide robust infrastructure to offer more clinical trial opportunities to our patients.”

The Alkek Foundation Center’s team practices across all specialty areas, allowing a broad swath of the Cancer Center’s patients to take part and to continue to receive care from the sub-specialty doctors they know and trust. And even if they aren’t already being treated at Baylor, physicians from outside Baylor can refer patients to the program through a smooth process.

“We are excited to offer novel research treatment options to our cancer patients at our state-of-the-art unit,” says Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center and senior associate dean of cancer programs at Baylor. “This program will increase the scope of our research while giving the cancer patients in our community access to first in human and cutting-edge clinical trials.”

Patients will be treated at Duncan Cancer Center’s clinical home, Baylor St. Luke’s Medical Center’s O’Quinn Medical Tower at the McNair Campus. As interim dean of research and dean of the Graduate School of Biomedical Sciences at Baylor, Carolyn Smith says, with the new center, Baylor is “advancing medicine by taking innovations made in the lab and moving them to the bedside.”

The debut trial to take place at the center enrolled its first patient this month. It will test a novel therapy that targets a mutation commonly found in pancreatic and colorectal cancers.

“Phase 1 oncology clinical trials provide patients early access to cutting-edge therapeutics and immunotherapies that are not widely available. Patients in these trials are often selected because their tumors have a molecular feature that is targeted by these therapies,” says Dr. S. Gail Eckhardt, who is Baylor’s Albert and Margaret Alkek endowed chair and serves as associate dean for experimental therapeutics at Baylor and associate director of translational research at the Duncan Cancer Center.

A Houston company with a promising immuno-oncology is one step closer to delivering its cancer-fighting drug to patients who need it. Photo via Getty Images

Houston immuno-oncology company reaches next FDA milestone, heads to phase 2 trial

green light

A Houston immuno-oncology company has recently made major headway with the FDA, including both a fast track and an orphan drug designation. It will soon start a phase 2 trial of its promising cancer fighting innovation.

Diakonos Oncology was born in 2016, the brainchild of Baylor researchers already hard at work in the realm of dendritic cell vaccines. Drs. Will Decker, Matt Halpert, and Vanaja Konduri partnered with Dan Faust, a Houston businessman and pharmacist, to bring their treatment to the public, says COO Jay Hartenbach.

The name Diakonos means “deacon or servant in Greek,” he explains. “A lot of companies end up focusing on treating a specific disease or cancer and what you end up having is a significant amount of potential but with a lot of tradeoffs and downsides. And so our goal is we need to eliminate the cancer but we can't harm or dramatically malign the patient in doing so.”

How do they do that? Because the therapy catalyzes a natural immune response, it’s the patient’s own body that’s fighting the cancer. Hartenbach credits Decker with the idea of educating dendritic cells to attack cancer, in this case, glioblastoma multiforme (GBM), one of the most aggressive cancers with which doctors and patients are forced to tangle.

“Our bodies are already very good at responding very quickly and aggressively to what it perceives as virally infected cells. And so what Dr. Decker did was basically trick the immune system by infecting these dendritic cells with the cancer specific protein and mRNA,” details Hartenbach.

Jay Hartenbach is the COO of Diakonos Oncology. Photo courtesy of Diakonos Oncology

But GBM isn’t the only cancer on which Diakonos Oncology has its sights set. Other notably stubborn-to-treat cancers that they’re working on include pancreatic cancer and angiosarcoma. The scientists are focused on meeting unmet medical needs, but also realize that treating such cancers would allow for the fastest determination of whether or not the treatment was effective.

The fast track designation, originally received last fall, means that the drug approval time for DOC1021, Diakonos’ glioblastoma vaccine, will be only six months. But Hartenbach highlights an additional boon, the fact that the special designation also allows for more frequent communications with the FDA.

“That’s very helpful for us, right as we're contemplating how to design the upcoming trials. From a business standpoint, it also is incredibly helpful because it provides a third party validation of what we're doing and the results that we're seeing,” he says.

What they’re seeing includes the survival of 13 out of 16 patients from the initial October 2021 enrollment. The three patients who passed away received the lowest dose of DOC1021. Hartenbach says that the remaining patients are thriving, with no serious adverse effects. With a median survival rate of 15 to 21 months, it’s hard to understate the significance of these patients’ success.

Diakonos Oncology is headquartered in Houston, with a staff of 10 in Space City and an additional eight distributed employees. Hartenbach says that the company’s hometown has been instrumental in its success. He mentions that the robust innovation of the Texas Medical Center meant that as the company has grown, there has never been a motivation to leave Houston.

“You're having a lot of both investment and companies actually moving to Houston,” Hartenbach says. “So we’ve been fortunate to have started there. There are bigger traditional biotech hubs, San Diego, Boston, and San Francisco, but Houston really is now putting itself on the map and it's getting a lot of attention.”

One of the companies responsible for that improved reputation? Diakonos Oncology and its promising approach to aggressive cancers.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

TMC med-tech company closes $2.5M series A, plans expansion

fresh funding

Insight Surgery, a United Kingdom-based startup that specializes in surgical technology, has raised $2.5 million in a series A round led by New York City-based life sciences investor Nodenza Venture Partners. The company launched its U.S. business in 2023 with the opening of a cleanroom manufacturing facility at Houston’s Texas Medical Center.

The startup says the investment comes on the heels of the U.S. Food and Drug Administration (FDA) granting clearance to the company’s surgical guides for orthopedic surgery. Insight says the fresh capital will support its U.S. expansion, including one new manufacturing facility at an East Coast hospital and another at a West Coast hospital.

Insight says the investment “will provide surgeons with rapid access to sophisticated tools that improve patient outcomes, reduce risk, and expedite recovery.”

Insight’s proprietary digital platform, EmbedMed, digitizes the surgical planning process and allows the rapid design and manufacturing of patient-specific guides for orthopedic surgery.

“Our mission is to make advanced surgical planning tools accessible and scalable across the U.S. healthcare system,” Insight CEO Henry Pinchbeck said in a news release. “This investment allows us to accelerate our plan to enable every orthopedic surgeon in the U.S. to have easy access to personalized surgical devices within surgically meaningful timelines.”

Ross Morton, managing Partner at Nodenza, says Insight’s “disruptive” technology may enable the company to become “the leader in the personalized surgery market.”

The startup recently entered a strategic partnership with Ricoh USA, a provider of information management and digital services for businesses. It also has forged partnerships with the Hospital for Special Surgery in New York City, University of Chicago Medicine, University of Florida Health and UAB Medicine in Birmingham, Alabama.

2 Houston suburbs named among 10 best places to live by U.S. News & World Report

Where to Live

The Houston suburbs of Pearland and League City have landed among the top 10 best places to live in 2025, according to U.S. News & World Report.

New for the 2025-2026 "Best Places to Live in the U.S." rankings, U.S. News expanded its coverage from 150 to 250 U.S. cities, and updated its methodology to examine each city based on five livability indexes: Quality of life, value, desirability, job market, and net migration.

Pearland ranked No. 3 nationwide, earning a 7.0 score alongside No. 1-winning Johns Creek, Georgia and No. 2 winner Carmel, Indiana.

Pearland also landed on top of U.S. News separate rankings of the best places to live in Texas for 2025-2026.

Some facts about Pearland that put it at the top of the list include its median household income ($115,504), its median home values ($319,753), and its bustling population of nearly 124,000 residents.

Housing costs in Pearland are extremely attractive compared to other places in the country, as the national average home is worth over $370,000. It's no wonder this Houston neighbor has been adding more high-income households than many other places in Texas.

Pearland's population is a healthy mix of young individuals and families, with 29 percent of residents under 20 years old and 36 percent of the population between the ages of 20-44. Nearly a quarter of Pearland's population is between 45-64-years-old, while only 12 percent of residents are over 65, the report says.

Pearland's reputation as one of the safest cities in America is also boosting its community appeal.

Pearland's Pear-Scape Trail is a popular public art trail that residents, families, and visitors can enjoy. The sculptures are scattered all over the city.City of Pearland - Government/Facebook

"Finding a community to be part of can play a major role in making a place feel like home," U.S. News said. "If you’re a parent with young children, you may want to live in a neighborhood with other people in that phase of life. If you’re a professional moving to a hot job market for your field, you may want to live in an apartment close to the office or within walking distance of friends and colleagues."

Pearland also enjoys a better job market than other cities, the report added. Pearland's unemployment rate as of 2023 was only 3.6 percent, lower than the national average unemployment rate of 4.5 percent.

However, if people are looking for a public transportation-friendly city, they may need to look elsewhere. Almost all commuters in Pearland drive to their workplaces, making access to a vehicle absolutely necessary for living in the suburb. Pearland's 31.2-minute average commute time is also 9.2 minutes higher than the national average, U.S. News said.

Other Houston-area suburbs

League City ranked three spots behind Pearland as the 6th best place to live in the U.S., and No. 2 in Texas. The city boasts a median household income of $120,670, and affordable median home values at $327,511.

Workers in League City also predominantly rely on vehicles for their daily commutes, and only 3.7 percent of the population use public transport to get to work. Commuters spend an average time of 27.5 minutes driving to work, U.S. News determined.

More than half (63.5 percent) of all League City residents are married, and 54 percent of the population are between the ages of 25 and 64-years-old.

Here's how other Houston-area cities faired among the top 100:

No. 16 – Sugar Land
No. 44 – The Woodlands
No. 45 – Katy
No. 67 – Missouri City
No. 73 – Spring

Houston drops out of the top 100

Though Houston proper made substantial improvements to land among the top 100 best places to live in U.S. News' 2024-2025 report, the city has once again plummeted toward the bottom of the list for 2025-2026.

Houston slumped to No. 381 this year, and only ranked No. 63 in the statewide comparison, showing that the city has lost its charm in favor of its appealing suburban neighbors.

The top 10 best places to live in the U.S. are:

No. 1 – Johns Creek, Georgia
No. 2 – Carmel, Indiana
No. 3 – Pearland, Texas
No. 4 – Fishers, Indiana
No. 5 – Cary, North Carolina
No. 6 – League City, Texas
No. 7 – Apex, North Carolina
No. 8 – Leander, Texas
No. 9 – Rochester Hills, Michigan
No. 10 – Troy, Michigan

---

This story originally appeared on CultureMap.com.

9 can't-miss Houston business and innovation events for June

where to be

Editor's note: From lightning pitches to a female-focused AI summit and energy conferences, there's still plenty to do as Houston settles into the summer. Here are the Houston business and innovation events you can't miss in June and how to register. Please note: this article might be updated to add more events.

June 3 – Founders Live Houston

Watch five Houston founders present their 99-second pitches at Founders Live Houston. Competing teams include AyeDu (Vinita Gupta), Omniscale (Tony Hernandez-Ferman), AnswerPath (Chris Mullins), Katana.video (Sam Bhattacharyya) and TraceWrap (Laketta B.).

This event is Tuesday, May 3, at 5:30 p.m. at the Ion. Register here.

June 4 – Center for Human Performance Research & Networking Event

Rice University and Houston Methodist's Center for Human Performance will host an event to support its work in the study of exercise physiology, injury prevention and rehabilitation. The organizations will share more information on seed grant opportunities, and the event will feature presentations from Rice and Houston Methodist leaders, networking sessions and a poster showcase.

This event is Wednesday, June 4, from 3-5:30 p.m. at the BioScience Research Collaborative at Rice University. Register here.

June 12 – Transition on Tap

Meet and hear lighting pitches from eight of Greentown Labs’ newest startup members. Attendees can network with entrepreneurs, investors, corporate leaders, philanthropists, students and other climate champions. Georgina Campbell Flatter, CEO of Greentown Labs, and Victor Martinez, Greentown's memberships manager, will also speak.

This event is Thursday, June 12, from 5:30-7:30 p.m. at Greentown Houston. Register here.

June 16-18 — Energy Drone & Robotics Summit

This three-day summit, the largest of its kind, will connect 1,500-plus leaders in the global energy/industrial robotics, drone and data sectors. Attendees will glean the latest ideas, use cases, best practices, tech and trends from a wide variety of robotics and drone industry experts.

This event begins June 16 at Woodlands Waterway Marriott. Register here.

June 17 – SGSF’s #SUPERGirlsInSTEM Summit, The Intersection of AI & Workforce

SUPERGirls SHINE Foundation is hosting a one-day summit for women ages 18-24 focused on the evolving intersection of AI and the STEM workforce. The conference will feature keynote speakers, panel discussions and hands-on workshops.

This event is Tuesday, June 17, from 9 a.m.-1 p.m. at the Ion. Register here.

June 18 – 2025 Obsidi BNXT: Juneteenth Tech Forum

Obsidi.com, an online platform launched by the Black Professionals in Tech Network (BPTN), will host a forum for high-performing Black and allied tech executives. The event offers networking opportunities, keynotes and panels that feature executives from Echelon Health Partners, Hewlett-Packard Enterprise, SAP, Intuit and more.

The event is Wednesday, June 18, at NRG Center. Register here.

June 24 — Houston Methodist Leadership Speaker Series

Head to the Houston Methodist Tech Hub at Ion to hear the latest installment of the Houston Methodist Leadership Speaker Series. Trent Fulin, vice president and CEO at Houston Methodist Cypress Hospital, will discuss the new 105-acre campus and its first 100 days of patient care, followed by a Q&A.

This event is Tuesday, June 23, from 4:45-6 p.m. Register here.

June 25-26 – Carbon Capture Technology Expo and Hydrogen Technology Conference & Expo North America

Tackling climate change is one of the biggest global challenges that requires immediate action, and many industrial sectors are now looking to new technology to help meet net-zero emission targets. The Carbon Capture Technology Expo is North America's leading event for carbon capture, utilization and storage. The expo offers opportunities to network with industry frontrunners and best-in-class solution providers.

This event begins June 25 at NRG Center. Click here to register. It is co-located with the Hydrogen Technology Conference & Expo North America. Expo passes are free.

June 26 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing and how Houston’s innovation community can leverage them. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 26, from 6-7 p.m. at the Ion. Register here.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME